Antimetabolite acting primarily on cells in S phase. It is used in patients with myeloproliferative disorders.
Cutaneous manifestations: 10 to 35% of patients.
Fever: 15 cases published (up to 1997).
General: fever, appearing within the first few weeks after first exposure;
disappearing rapidly after discontinuation.
Cutaneous: generalized dryness and scaling (xerosis), dermatomyositis-like eruption (dorsal hands), cutaneous atrophy, hyperpigmentation of skin and nails, ulcerative lichen planus-like dermatitis, fixed drug eruption (rare), oral or leg ulceration.
Respiratory: alveolitis (rare).
Skin biopsy: epidermal thickening, flattening of the dermoepidermal junction, basal layer degeneration, colloid body formation.
Cutaneous reactions: Lichenoid hypersensitivity reaction?
Hydroxyurea toxicity on the basal layer of the epidermis?
Hydroxyurea can be continued if necessary with no worsening of cutaneous lesions.